CD36 and cancer: Since CSCs are subpopulations of cancer cells that exhibit a self-renewal capability and resistance to chemotherapies, targeting CD36 may offer a strategy to target these notoriously difficult-to-eliminate populations responsible for therapy relapses among patients.